GlobeStar Therapeutics Corp (GSTC) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
719 JADWIN AVENUE RICHLAND, WA 99352 |
| State of Incorp. | WY |
| Fiscal Year End | September 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 6/30/2024 Q3 | 3/31/2024 Q2 | 12/31/2023 Q1 | 9/30/2023 Q4 | 6/30/2023 Q3 | 3/31/2023 Q2 | 12/31/2022 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 0 | 8 | |||||||
| Cash and cash equivalent | 0 | 8 | |||||||
| Prepaid expense | 148 | 3 | |||||||
| Deferred costs | 2 | 1 | |||||||
| Total current assets: | 148 | 2 | 1 | 0 | 10 | ||||
| Noncurrent Assets | |||||||||
| TOTAL ASSETS: | 148 | 2 | 1 | 0 | 10 | ||||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 586 | 505 | 455 | 488 | 450 | 417 | |||
| Accounts payable | 408 | 366 | 328 | 200 | 163 | 138 | |||
| Accrued liabilities | 224 | 227 | 525 | 224 | 224 | 224 | |||
| Other undisclosed accounts payable and accrued liabilities | (46) | (88) | (399) | 64 | 64 | 56 | |||
| Debt | 32 | 79 | 360 | 16 | 20 | ||||
| Due to related parties | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 500 | ||
| Other undisclosed current liabilities | 999 | 949 | 619 | 773 | 841 | 311 | |||
| Total current liabilities: | 1,616 | 1,533 | 1,434 | 1,277 | 1,291 | 1,248 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 1,616 | 1,533 | 1,434 | 1,277 | 1,291 | 1,248 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (1,469) | (1,533) | (1,434) | (1,277) | (1,291) | (1,238) | |||
| Common stock | 1,163 | 1,050 | 996 | 872 | 780 | 770 | |||
| Additional paid in capital | 18,013 | 18,067 | 18,023 | 17,920 | 16,723 | 16,651 | |||
| Accumulated deficit | (20,825) | (20,650) | (20,454) | (20,103) | (18,821) | (18,671) | |||
| Other undisclosed equity, attributable to parent | 180 | 1 | 1 | 34 | 27 | 12 | |||
| Total equity: | (1,469) | (1,533) | (1,434) | (1,277) | (1,291) | (1,238) | |||
| TOTAL LIABILITIES AND EQUITY: | 148 | 0 | 10 | ||||||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 6/30/2024 Q3 | 3/31/2024 Q2 | 12/31/2023 Q1 | 9/30/2023 Q4 | 6/30/2023 Q3 | 3/31/2023 Q2 | 12/31/2022 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Net Investment Income) | 32 | |||||||
| Gross profit: | 32 | |||||||
| Operating expenses | (168) | (156) | (288) | (1,279) | (142) | (155) | ||
| Other undisclosed operating loss | (32) | |||||||
| Operating loss: | (168) | (156) | (288) | (1,279) | (142) | (155) | ||
| Nonoperating expense | (7) | (8) | (63) | (3) | (8) | (11) | ||
| Interest and debt expense | (8) | (10) | (8) | (11) | ||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 8 | |||||||
| Net loss: | (175) | (164) | (351) | (1,292) | (158) | (177) | ||
| Other undisclosed net income attributable to parent | 10 | 8 | 11 | |||||
| Net loss available to common stockholders, diluted: | (175) | (164) | (351) | (1,283) | (150) | (166) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 6/30/2024 Q3 | 3/31/2024 Q2 | 12/31/2023 Q1 | 9/30/2023 Q4 | 6/30/2023 Q3 | 3/31/2023 Q2 | 12/31/2022 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (175) | (164) | (351) | (1,292) | (158) | (177) | ||
| Comprehensive loss, net of tax, attributable to parent: | (175) | (164) | (351) | (1,292) | (158) | (177) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.